CD3/CD19-depleted or CD3-depleted/CD56-selected haploidentical donor natural killer cell therapy
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for CD3/CD19-depleted or CD3-depleted/CD56-selected haploidentical donor natural killer cell therapy, covering 2017-12-02 to 2017-12-02. Get the full timeline:
Most recent: Clinical Trial Update: CD3/CD19 Depleted or CD3 Depleted/CD56 Selected Haploid Donor Natural Killer Cell Treatment in Older AML in First Complete Remission [Phase 2]